HALO — Halozyme Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Halozyme Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	443	660	829	1,015	1,397
Cost of Revenue
Gross Profit	362	521	637	856	1,168
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	188	395	492	464	933
Operating Profit	255	265	338	551	464
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	249	249	348	557	467
Provision for Income Taxes
Net Income After Taxes	403	202	282	444	317
Net Income Before Extraordinary Items
Net Income	403	202	282	444	317
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	403	202	282	444	317
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.84	1.58	2.11	3.43	5.23